ADVISORY, Jan. 26, 2017 --
What:
ObsEva SA (Nasdaq:OBSV), a biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that impact a woman’s reproductive health and pregnancy, will visit the Nasdaq MarketSite in Times Square, in celebration of its initial public offering (IPO).
In honor of the occasion, Ernest Loumaye, Co-Founder and CEO, will ring the Opening Bell.
Where:
Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio
When:
Thursday, January 26, 2017 – 9:15 a.m. to 9:30 a.m. ET
ObsEva Contact:
Liz Bryan
Spectrum Science
[email protected]
202-955-6222 x2526
Nasdaq MarketSite:
Emily Pan
(646) 441-5120
[email protected]
Feed Information:
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0
DVBS QPSK
Social Media:
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page:
http://www.facebook.com/NASDAQ.
For photos from ceremonies and events, please visit our Instagram page:
http://instagram.com/nasdaq
For livestream of ceremonies and events, please visit our YouTube page:
http://www.youtube.com/nasdaq/live
For news tweets, please visit our Twitter page:
http://twitter.com/nasdaq
For exciting viral content and ceremony photos, please visit our Tumblr page:
http://nasdaq.tumblr.com/
Webcast:
A live stream of the Nasdaq Opening Bell will be available at:
https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos:
To obtain a hi-resolution photograph of the Market Open, please go to http://business.nasdaq.com/discover/market-bell-ceremonies and click on the market open of your choice.
About ObsEva
ObsEva is a biopharmaceutical company innovating women’s reproductive health and pregnancy therapeutics from conception to birth. Between the ages of 15 and 49, millions of women worldwide suffer from reproductive health conditions that affect their quality of life or their ability to conceive and may lead to complications during pregnancy. ObsEva aims to improve upon the current treatment landscape with the development of novel, oral medicines with potentially best-in-class safety and efficacy profiles. Through strategic in-licensing and disciplined drug development, ObsEva has established a clinical-stage pipeline with multiple development programs focused on treating the symptoms associated with uterine fibroids and endometriosis, improving clinical pregnancy and live birth rates in women undergoing in vitro fertilization, and treating preterm labor. For more information, please visit www.ObsEva.com.
About Nasdaq
Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables clients to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 85 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to approximately 3,800 listed companies with a market value of $10.1 trillion and approximately 18,000 corporate clients. To learn more, visit: business.nasdaq.com.
-NDAQA-


Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 



